Actively Recruiting
Open-label Study to Evaluate Safety and Efficacy of ACE1831 Cell Therapy in Adults with IgG4-Related Disease
Led by Acepodia Biotech, Inc. · Updated on 2026-10-02
34
Participants Needed
11
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate ACE1831, an off-the-shelf allogeneic gamma delta T cell therapy derived from healthy donors, for treating people with Immunoglobulin G4 Related Disease IgG4-RD. The study is an open-label, multicenter trial with two treatment arms, focusing on assessing safety, efficacy, and how long ACE1831 persists in the body. The study involves adults aged 18 and older with active IgG4-RD flare affecting multiple organs. Participants are assigned to one of two arms receiving different dosing regimens of ACE1831. Some receive a single infusion with lymphodepleting chemotherapy conditioning, while others receive two infusions without this preconditioning. An expansion cohort may receive two infusions at the dose and regimen selected by a Safety Review Committee. The chemotherapy preconditioning involves drugs fludarabine and cyclophosphamide given before ACE1831. During the study, participants undergo regular monitoring including adverse event assessments, lab tests, physical exams, ECGs, and vital signs up to 72 weeks after the first dose. Researchers measure safety and tolerability primarily, and also assess efficacy through remission rates, flare timing, glucocorticoid use, and changes in several patient-reported and clinical indices. The total follow-up includes up to 72 weeks post-treatment to track outcomes and persistence of the therapy.
CONDITIONS
Brief Title
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
Research Team
A
Acepodia Clinical Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here